Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1420

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 6
Chunk 1420
---
 of our historical recurring losses and negative cash flows from operations as well as our dependence
on financings. See “Risk Factors—We have a history of operating losses, our management has concluded that factors raise substantial
doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to
continue as a going concern in its audit report for the fiscal years ended December 31, 2024 and 2023.

Our
failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business
strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors,
including:

    ●
    the
    scope, rate of progress and costs of our drug delivery, preclinical development activities, laboratory testing and clinical trials
    for our drug candidate;

    ●
    the
    number and scope of clinical programs we decide to pursue;

    ●
    the
    scope and costs of manufacturing development and commercial manufacturing activities;

    ●
    the
    extent to which we acquire or in-license other drug candidate and technologies;

    ●
    the
    cost, timing and outcome of regulatory review of our drug candidate;

    ●
    the
    cost and timing of establishing sales and marketing capabilities, if our drug candidate receives marketing approval;

    ●
    the
    costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights
    and defending intellectual property-related claims;

    ●
    our
    ability to establish and maintain collaborations on favorable terms, if at all;

    ●
    our
    efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support
    the development of our drug candidate;

    ●
    the
    costs associated with being a public company; and

    ●
    the
    cost associated with commercializing our drug candidate, if it receives marketing approval.

85

If
we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which
we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or
additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or
asset sale transactions. Any debt financing or additional equity that we raise may contain